Hospital trust continues to battle £18.6m deficit
The Shrewsbury and Telford Hospitals NHS Trust board was told it had posted an £18.6m deficit at the end of the financial year.
However, trust chairman Andrew Morgan said the figures were "misleading" in light of it having receiving two support packages of £44m and £10m and without them, the deficit would have been "the £70s of millions".
He added: "That is unacceptable, stating the blindingly obvious."
The position has improved as the trust previously posted a deficit as high as £100m, the Local Democracy Reporting Service said.
The trust has been told it will not have to get a balanced budget in one financial year.
Richard Miner, who chairs the trust's Finance Assurance Committee, said: "We have got to be on the button in terms of performance. It is a big year."
He said the trust was looking to use new technology to reduce its reliance on agency staff
But the possibility of redundancies among the near 8,000 strong workforce was not discussed at Thursday's meeting and a recruitment freeze for "non-critical" roles remains in place.
Jo Williams, the trust's chief executive, said she was "being honest" about the challenges the organisation faced but promised the trust would "not compromise on patient safety".
The board was told that it had cash balances of £61.8m but a new modular ward would require "substantial outlay and cash balances will need to be monitored closely".
This news was gathered by the Local Democracy Reporting Service which covers councils and other public service organisations.
Follow BBC Shropshire on BBC Sounds, Facebook, X and Instagram.
Park-and-ride hospital buses to be made permanent
Health secretary asked to meet over troubled trust
Temporary drop-off area introduced at hospital
Hospital action plan after undercover documentary
Shrewsbury and Telford Hospital Trust
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Postcode lottery for Mounjaro, the 'King Kong' of weight loss jabs, with only eight NHS care boards providing treatment
Thousands of severely obese patients are facing severely delayed treatment with what's been called the 'King Kong' of weight loss jabs - because the NHS rollout has been mismanaged and underfunded, according to Sky News research. Mounjaro was supposed to be available through GP surgeries and other community services from 23 June under an agreement between NHS England and the National Institute for Health and Care Excellence (NICE), the body that provides guidance on the use of new drugs. But Freedom of Information requests by Sky News reveal a postcode lottery, with only eight of 42 NHS Integrated Care Boards (ICBs) in England telling us they were providing treatment to patients, and many of the rest unable to guarantee when it would be available. The research also shows that at least 19 had a cap on how many eligible patients they would treat in the first year. Dr Jonathan Hazlehurst, an specialist at University Hospitals Birmingham, said many patients were desperate for treatment - and Mounjaro may be a hopeful aid for those eligible. "Giving people open promises and setting them up for disappointment and failure is clearly grossly unfair," he said. "That's what the current system is doing." NICE said in December that the NHS should offer Mounjaro to patients with a BMI over 40 and at least four clinical conditions related to their weight, such as heart disease or type 2 diabetes. It calculated from NHS England data that there were 97,500 patients who should be treated in the first year. But Dr Hazelhurst says NHS England has only provided funding for just over 22,000 patients. Read more: "It shows that there's a lack of political will to fund this adequately," he said. "NHS England says that obesity costs the NHS £11.4bn per annum as a pure NHS cost. "Yet we can't even afford to properly fund the rollout of a life-changing drug in year one. That just doesn't make any sense." Gary - who doesn't want his surname used - weighs 25 stone (158kg) and becomes severely out of breath after climbing only a few stairs. He is eligible for treatment with Mounjaro under the agreed NHS guidelines. But his surgery said "no" and told him it would be at least the autumn before the drug would be available in the Hampshire area. "They said to us that September would be the earliest they going to look at it and then the criteria might change, so there's no knowing if I'm going to get it," he said. "I was so excited when I read about this drug. If I had the drug and lost some weight, it could help me move around, it could help me go fishing again, all kinds of things. "It's not for vanity. It would be a life changer." There are 3.4 million people in England who would qualify for treatment under the NICE eligibility criteria. But NHS England has said it will take 12 years to assess and prescribe to those who need it. Dr Hazlehurst said there would never be such a slow rollout with a new cancer treatment - and yet, obesity also kills. "There's a huge amount of stigma that drives things to do with obesity care all across the system," he said. "The 'eat less, move more' nonsense doesn't help. "That is a really unhelpful, harmful and stigmatising approach, particularly in an age of effective treatment." Read more from Thomas Moore: A spokesperson for NHS England said it had "fully supported the rollout" of Mounjaro. They said: "We issued guidance and provided funding in March to all Integrated Care Boards to support treatment costs, enable scaling of services and provide wrap-around care, including digital support services."
Yahoo
an hour ago
- Yahoo
Hims & Hers Health Inc (HIMS) Q2 2025 Earnings Call Highlights: Robust Revenue Growth Amid ...
Revenue: $545 million, a 73% year-over-year increase. Adjusted EBITDA Margin: Over 15%. Subscribers: Increased by 73,000 quarter over quarter to over 2.4 million, a 31% year-over-year growth rate. Monthly Average Revenue per Subscriber: Declined quarter over quarter to $74 from $84. Gross Margin: Expanded 3 points quarter over quarter to 76%. Cash and Short-term Investments: Over $1.1 billion at the end of the second quarter. Free Cash Flow: Negative $69 million for the second quarter. Third Quarter Revenue Guidance: Expected between $570 million to $590 million. Full Year Revenue Guidance: Expected between $2.3 billion and $2.4 billion. Full Year Adjusted EBITDA Guidance: Expected between $295 million to $335 million. Warning! GuruFocus has detected 5 Warning Sign with HIMS. Release Date: August 04, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Hims & Hers Health Inc (NYSE:HIMS) reported a 73% year-over-year revenue growth to $545 million in Q2 2025, with an adjusted EBITDA margin exceeding 15%. The company is expanding its platform with new specialties, including hormonal health, which is expected to address significant health issues for both men and women. Hims & Hers Health Inc (NYSE:HIMS) successfully acquired ZAVA, enhancing its presence in the UK and establishing a foundation for further expansion in Europe and Canada. The company is investing in AI and technology to enhance personalized care, aiming to provide 24/7 support and improve patient engagement. Hims & Hers Health Inc (NYSE:HIMS) plans to offer lab testing as a standalone service, which is expected to empower customers with better health insights and proactive health management. Negative Points The company faced headwinds from off-boarding GLP-1 subscribers on commercially available dosages, impacting revenue recognition. There is a decline in the on-demand sexual health subscriber base, which is expected to continue affecting revenue in the short term. Hims & Hers Health Inc (NYSE:HIMS) reported a negative free cash flow of $69 million in Q2 2025 due to significant investments in inventory and working capital. The transition towards more premium daily offerings in the sexual health segment is causing temporary revenue declines. The company anticipates increased marketing and technology investments, which may pressure margins in the near term. Q & A Highlights Q: Why was now the right time to expand internationally, and what made ZAVA the right company to acquire? A: Andrew Dudum, CEO, explained that the acquisition of ZAVA is a strategic move to replicate Hims & Hers' personalized, high-touch, affordable precision medicine model in key international markets. ZAVA's ability to scale in unique regulatory environments was a key factor in the acquisition. The international market is seen as a focused effort, with a multibillion-dollar revenue opportunity in a few key markets. Q: How does the launch of at-home lab testing improve the business and support the broader mission of Hims & Hers? A: Andrew Dudum, CEO, emphasized that at-home lab testing is foundational for transitioning healthcare from treatment to prevention. It simplifies necessary tests, makes them affordable, and educates patients on optimal health metrics. This initiative is expected to open membership opportunities similar to Amazon or Costco, focusing on preventative health. Q: Can you provide insights into the core business dynamics and expectations for Q3, especially regarding the personalized GLP-1 offering? A: Oluyemi Okupe, CFO, noted material headwinds in the GLP-1 segment due to off-boarding commercially available dosages. The core business is experiencing a drag from the sexual health on-demand segment, but specialties like dermatology and weight loss are growing robustly. The transition to daily offerings in sexual health is expected to improve retention and customer lifetime value. Q: What are the expectations for the Canadian expansion and the impact of generic semaglutide pricing? A: Andrew Dudum, CEO, stated that the Canadian expansion will leverage ZAVA's expertise, with offerings under the Hims & Hers brand. The generic semaglutide is expected to be priced significantly lower than branded options, unlocking substantial market access in Canada, where a large portion of the population is affected by weight issues. Q: How is the Hers business performing, and what are the key growth drivers? A: Oluyemi Okupe, CFO, reported robust growth in the Hers business, driven by dermatology, weight loss, and mental health offerings. The upcoming launch of hormonal support for menopause is expected to further catalyze growth. Q: What is the approach to AI investments, and what impact is expected on the business? A: Andrew Dudum, CEO, highlighted a strategy focused on immediate, tactical improvements through AI. The platform's extensive patient interactions allow for rapid deployment of AI use cases, aiming to enhance efficiency and engagement across the provider, patient, and pharmacist interfaces within 3 to 6 months. Q: Can you discuss the marketing strategy and patient acquisition costs for the second half of the year? A: Oluyemi Okupe, CFO, stated that marketing investments will be robust but adhere to a capital allocation framework with a payback period of less than a year. The focus will be on specialty-specific investments and talent acquisition to support new specialties and international expansion. Q: What are the expectations for inventory levels and supply chain management? A: Oluyemi Okupe, CFO, explained that inventory levels increased to ensure a durable supply for new specialties and to leverage the strong balance sheet amid global uncertainties. This is seen as an anomaly, with future inventory adjustments expected to stabilize. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Medscape
an hour ago
- Medscape
High Lp(a) Signals Risk Beyond The Coronaries
TOPLINE: Elevated levels of lipoprotein(a) [Lp(a)] were associated with significantly increased risks for incident peripheral artery disease and carotid artery stenosis. Among patients with peripheral artery disease, those with high levels of Lp(a) (≥ 150 nmol/L) had a high risk of progressing to major adverse limb events. METHODOLOGY: Despite lifestyle interventions and therapies for lowering levels of cholesterol, a residual risk for major atherosclerotic complication persists. Researchers analyzed data from a large prospective biobank (2006-2010) to investigate whether baseline levels of Lp(a) predict the risk for onset and progression of extracoronary atherosclerotic vascular disease — a combination of peripheral artery disease and carotid artery stenosis. The UK biobank data included 460,544 individuals (average age at enrollment, 57 years; 54.2% men; 94.9% European) and followed them for a median duration of 13.6 years. Data on baseline serum levels of Lp(a) were retrieved, with levels ≥ 150 nmol/L (about 70 mg/dL) defined as high. The analysis assessed the incidence of peripheral artery disease and carotid artery stenosis and the progression to both the first major adverse limb event and first stroke. TAKEAWAY: Individuals with high levels of Lp(a) were older and more often men than those with normal levels of Lp(a) (P < .001 for both). Each 75-nmol/L (35 mg/dL) increase in levels of Lp(a) was associated with a 1.18-fold elevated risk for incident peripheral artery disease and a 1.17-fold increased risk for incident carotid artery stenosis (P < .0001 for both). Among patients with peripheral artery disease, those with high levels of Lp(a) had a 1.6-fold higher risk of developing major adverse limb events than those with normal levels of Lp(a) (P = .004). IN PRACTICE: 'Participants with established atherosclerotic vascular disease and elevated Lp(a) concentrations may represent the ideal group to benefit from targeted preventive interventions,' the researchers noted. '[The study's] findings make a strong case to explore the effect of therapies to lower Lp(a) in participants with PAD [peripheral artery disease] and carotid stenosis towards the goal of slowing disease progression and reducing major complications of amputation and stroke,' they added. SOURCE: This study was led by Tiffany R. Bellomo, MD, of Broad Institute of Harvard and MIT, Cambridge, Massachusetts. It was published online on July 28, 2025, in Circulation. LIMITATIONS: Measuring Lp(a) using immunoassays may be inaccurate for individuals with large Lp(a) isoforms. This study lacked measurement of ankle-brachial index to define peripheral arterial disease. The analysis may not have accounted for all potential confounding factors. DISCLOSURES: This study received grants from the National Heart, Lung, and Blood Institute and the National Human Genome Research Institute. One author reported receiving research grants and personal fees from several pharmaceutical and healthcare companies and holding equity in multiple healthcare data and biotech firms. The same author reported spousal employment at a pharmaceutical company. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
